Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ABBOTT LABORATORIESABT · Entity 2314 | Director | April 24, 2026 | April 28, 2026 |
| Accenture plcACN · Entity 2893 | Director | August 14, 2026 | August 17, 2026 |
| Mondelez International, Inc.MDLZ · Entity 2953 | Director | May 20, 2026 | May 21, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ABBOTT LABORATORIES
Report date April 24, 2026 · Filed April 28, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common shares without par valueSEC Table I · non-derivative | Direct | 41,010 |
Reported balance
After 2026-04-24 transaction · row 1
1 source rowRow 1 · 2026-04-24 · Grant · Acquired 2,286 · Balance 41,010 F1: Restricted stock unit award granted under the Abbott Laboratories 2026 Incentive Stock Program (the "Program"). The award will be paid, on a one-to-one basis, in Abbott common shares on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program). |
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $91.86 · Expires 2036-04-23 | Direct | 2,305 |
Reported balance
After 2026-04-24 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-04-24 · Grant · Acquired 2,305 · Balance 2,305 F2: Stock option granted under the Program, in a transaction exempt from Section 16 under Rule 16b-3. |
Filing footnotes · ownership attribution and instrument terms
F1: Restricted stock unit award granted under the Abbott Laboratories 2026 Incentive Stock Program (the "Program"). The award will be paid, on a one-to-one basis, in Abbott common shares on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program).
F2: Stock option granted under the Program, in a transaction exempt from Section 16 under Rule 16b-3.
Accenture plc
Report date August 14, 2026 · Filed August 17, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A ordinary sharesSEC Table I · non-derivative | Direct | 8,107 |
Reported balance
After 2026-08-14 transaction · row 1
1 source rowRow 1 · 2026-08-14 · Grant · Acquired 12 · Balance 8,107 F1: Grant of Restricted Share Units (RSUs) pursuant to the anti-dilution provisions of previously granted RSU awards, to reflect Accenture plc's payment of a cash dividend. |
Filing footnotes · ownership attribution and instrument terms
F1: Grant of Restricted Share Units (RSUs) pursuant to the anti-dilution provisions of previously granted RSU awards, to reflect Accenture plc's payment of a cash dividend.
Mondelez International, Inc.
Report date May 20, 2026 · Filed May 21, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 6,634 |
Reported balance
After 2026-05-20 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-05-20 · Grant · Acquired 3,525 · Balance 6,634 F1: Grant of deferred stock units under the Issuer's 2024 Performance Incentive Plan. The deferred stock units are 100% vested, but receipt of the shares is deferred until the six-month anniversary of the reporting person's separation from service as a director of Mondelez International. F2: Total number of shares owned includes approximately 100 shares acquired through a dividend reinvestment program. |
Filing footnotes · ownership attribution and instrument terms
F1: Grant of deferred stock units under the Issuer's 2024 Performance Incentive Plan. The deferred stock units are 100% vested, but receipt of the shares is deferred until the six-month anniversary of the reporting person's separation from service as a director of Mondelez International.
F2: Total number of shares owned includes approximately 100 shares acquired through a dividend reinvestment program.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 14, 2026 Filed Aug 17, 2026 20:47 UTC | Accenture plc ACN · Entity 2893 | GrantClass A ordinary shares | 12 | $0.00 | $0.00 |
DisclosureSEC source: 0001294731-26-000006 · wk-form4_1786999655.xml · nonDerivative · entry 1 McKinstry Nancy · CIK 0001294731 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,107 F1 · shares: Grant of Restricted Share Units (RSUs) pursuant to the anti-dilution provisions of previously granted RSU awards, to reflect Accenture plc's payment of a cash dividend. Read SEC document |
| May 20, 2026 Filed May 21, 2026 23:10 UTC | Mondelez International, Inc. MDLZ · Entity 2953 | GrantClass A Common Stock | 3,525 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-037477 · wk-form4_1779405046.xml · nonDerivative · entry 1 McKinstry Nancy · CIK 0001294731 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,634 F1 · shares: Grant of deferred stock units under the Issuer's 2024 Performance Incentive Plan. The deferred stock units are 100% vested, but receipt of the shares is deferred until the six-month anniversary of the reporting person's separation from service as a director of Mondelez International. F2 · balance_after: Total number of shares owned includes approximately 100 shares acquired through a dividend reinvestment program. Read SEC document |
| May 15, 2026 Filed May 19, 2026 12:47 UTC | Accenture plc ACN · Entity 2893 | GrantClass A ordinary shares | 12 | $0.00 | $0.00 |
DisclosureSEC source: 0001294731-26-000005 · wk-form4_1779194876.xml · nonDerivative · entry 1 McKinstry Nancy · CIK 0001294731 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,095 F1 · shares: Grant of Restricted Share Units (RSUs) pursuant to the anti-dilution provisions of previously granted RSU awards, to reflect Accenture plc's payment of a cash dividend. Read SEC document |
| April 24, 2026 Filed Apr 28, 2026 23:02 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 2,305 | $0.00 Strike: $91.86 | $0.00 |
DisclosureSEC source: 0001294731-26-000004 · form4-04282026_110436.xml · derivative · entry 2 McKinstry Nancy · CIK 0001294731 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,305 Underlying: Common Shares · 2,305 shares Expires 2036-04-23 F2 · security: Stock option granted under the Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| April 24, 2026 Filed Apr 28, 2026 23:02 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 2,286 | $0.00 | $0.00 |
DisclosureSEC source: 0001294731-26-000004 · form4-04282026_110436.xml · nonDerivative · entry 1 McKinstry Nancy · CIK 0001294731 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,010 F1 · shares: Restricted stock unit award granted under the Abbott Laboratories 2026 Incentive Stock Program (the "Program"). The award will be paid, on a one-to-one basis, in Abbott common shares on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program). Read SEC document |
| February 13, 2026 Filed Feb 17, 2026 21:11 UTC | Accenture plc ACN · Entity 2893 | Tax withholdingClass A ordinary shares | 4 | $224.11 | $896.45 |
DisclosureSEC source: 0001294731-26-000003 · wk-form4_1771362704.xml · nonDerivative · entry 2 McKinstry Nancy · CIK 0001294731 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,083 Read SEC document |
| February 13, 2026 Filed Feb 17, 2026 21:11 UTC | Accenture plc ACN · Entity 2893 | GrantClass A ordinary shares | 7 | $0.00 | $0.00 |
DisclosureSEC source: 0001294731-26-000003 · wk-form4_1771362704.xml · nonDerivative · entry 1 McKinstry Nancy · CIK 0001294731 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,087 F1 · shares: Grant of Restricted Share Units (RSUs) pursuant to the anti-dilution provisions of previously granted RSU awards, to reflect Accenture plc's payment of a cash dividend. Read SEC document |
| February 06, 2026 Filed Feb 10, 2026 14:01 UTC | Accenture plc ACN · Entity 2893 | Tax withholdingClass A ordinary shares | 398 | $236.55 | $94,144.91 |
DisclosureSEC source: 0001294731-26-000002 · wk-form4_1770732100.xml · nonDerivative · entry 1 McKinstry Nancy · CIK 0001294731 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,080 Read SEC document |
| January 28, 2026 Filed Jan 29, 2026 21:16 UTC | Accenture plc ACN · Entity 2893 | GrantClass A ordinary shares | 1,212 | $0.00 | $0.00 |
DisclosureSEC source: 0001294731-26-000001 · wk-form4_1769721363.xml · nonDerivative · entry 1 McKinstry Nancy · CIK 0001294731 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,478 F1 · kind: Represents a grant of restricted share units awarded under the Accenture plc Amended and Restated 2010 Share Incentive Plan. Read SEC document |
| November 14, 2025 Filed Nov 18, 2025 21:22 UTC | Accenture plc ACN · Entity 2893 | GrantClass A ordinary shares | 6 | $0.00 | $0.00 |
DisclosureSEC source: 0001294731-25-000009 · wk-form4_1763500963.xml · nonDerivative · entry 1 McKinstry Nancy · CIK 0001294731 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,266 F1 · shares: Grant of Restricted Share Units (RSUs) pursuant to the anti-dilution provisions of previously granted RSU awards, to reflect Accenture plc's payment of a cash dividend. Read SEC document |
| August 15, 2025 Filed Aug 18, 2025 20:20 UTC | Accenture plc ACN · Entity 2893 | GrantClass A ordinary shares | 5 | $247.57 | $1,237.85 |
DisclosureSEC source: 0001294731-25-000008 · wk-form4_1755548447.xml · nonDerivative · entry 1 McKinstry Nancy · CIK 0001294731 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,260 F1 · shares: Grant of Restricted Share Units (RSUs) pursuant to the anti-dilution provisions of previously granted RSU awards, to reflect Accenture plc's payment of a cash dividend. Read SEC document |
| May 21, 2025 Filed May 22, 2025 20:28 UTC | Mondelez International, Inc. MDLZ · Entity 2953 | GrantClass A Common Stock | 3,009 | $0.00 | $0.00 |
DisclosureSEC source: 0001103982-25-000169 · wk-form4_1747945699.xml · nonDerivative · entry 1 McKinstry Nancy · CIK 0001294731 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,009 F1 · shares: Grant of deferred stock units under the Issuer's 2024 Performance Incentive Plan. The deferred stock units are 100% vested, but receipt of the shares is deferred until the six-month anniversary of the reporting person's separation from service as a director of Mondelez International. Read SEC document |
| May 15, 2025 Filed May 16, 2025 20:41 UTC | Accenture plc ACN · Entity 2893 | GrantClass A ordinary shares | 4 | $0.00 | $0.00 |
DisclosureSEC source: 0001467373-25-000136 · wk-form4_1747428088.xml · nonDerivative · entry 1 McKinstry Nancy · CIK 0001294731 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,255 F1 · shares: Grant of Restricted Share Units (RSUs) pursuant to the anti-dilution provisions of previously granted RSU awards, to reflect Accenture plc's payment of a cash dividend. Read SEC document |
| April 25, 2025 Filed Apr 29, 2025 21:58 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 1,465 | $0.00 Strike: $128.40 | $0.00 |
DisclosureSEC source: 0001415889-25-011525 · form4-04292025_090434.xml · derivative · entry 2 McKinstry Nancy · CIK 0001294731 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,465 Underlying: Common Shares · 1,465 shares Expires 2035-04-24 F2 · security: Stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| April 25, 2025 Filed Apr 29, 2025 21:58 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 1,635 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-011525 · form4-04292025_090434.xml · nonDerivative · entry 1 McKinstry Nancy · CIK 0001294731 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,724 F1 · shares: These are restricted stock units awarded under the Abbott Laboratories 2017 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in Abbott common shares on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program). Read SEC document |
| February 14, 2025 Filed Feb 18, 2025 21:27 UTC | Accenture plc ACN · Entity 2893 | Tax withholdingClass A ordinary shares | 2 | $389.22 | $778.43 |
DisclosureSEC source: 0001467373-25-000074 · wk-form4_1739914045.xml · nonDerivative · entry 2 McKinstry Nancy · CIK 0001294731 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,251 Read SEC document |
| February 14, 2025 Filed Feb 18, 2025 21:27 UTC | Accenture plc ACN · Entity 2893 | GrantClass A ordinary shares | 4 | $0.00 | $0.00 |
DisclosureSEC source: 0001467373-25-000074 · wk-form4_1739914045.xml · nonDerivative · entry 1 McKinstry Nancy · CIK 0001294731 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,253 F1 · shares: Grant of Restricted Share Units (RSUs) pursuant to the anti-dilution provisions of previously granted RSU awards, to reflect Accenture plc's payment of a cash dividend. Read SEC document |
| February 06, 2025 Filed Feb 7, 2025 21:26 UTC | Accenture plc ACN · Entity 2893 | GrantClass A ordinary shares | 813 | $0.00 | $0.00 |
DisclosureSEC source: 0001467373-25-000065 · wk-form4_1738963565.xml · nonDerivative · entry 1 McKinstry Nancy · CIK 0001294731 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,249 F1 · kind: Represents a grant of restricted share units awarded under the Accenture plc Amended and Restated 2010 Share Incentive Plan. Read SEC document |
| January 31, 2025 Filed Feb 4, 2025 21:18 UTC | Accenture plc ACN · Entity 2893 | Tax withholdingClass A ordinary shares | 419 | $383.32 | $160,611.08 |
DisclosureSEC source: 0001467373-25-000033 · wk-form4_1738703895.xml · nonDerivative · entry 1 McKinstry Nancy · CIK 0001294731 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,436 Read SEC document |
| November 15, 2024 Filed Nov 19, 2024 14:01 UTC | Accenture plc ACN · Entity 2893 | GrantClass A ordinary shares | 4 | $0.00 | $0.00 |
DisclosureSEC source: 0001467373-24-000329 · wk-form4_1732024893.xml · nonDerivative · entry 1 McKinstry Nancy · CIK 0001294731 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,855 F1 · shares: Grant of Restricted Share Units (RSUs) pursuant to the anti-dilution provisions of previously granted RSU awards, to reflect Accenture plc's payment of a cash dividend. Read SEC document |
| August 15, 2024 Filed Aug 16, 2024 20:15 UTC | Accenture plc ACN · Entity 2893 | GrantClass A ordinary shares | 4 | $0.00 | $0.00 |
DisclosureSEC source: 0001467373-24-000240 · wk-form4_1723839343.xml · nonDerivative · entry 1 McKinstry Nancy · CIK 0001294731 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,851 F1 · shares: Grant of Restricted Share Units (RSUs) pursuant to the anti-dilution provisions of previously granted RSU awards, to reflect Accenture plc's payment of a cash dividend. Read SEC document |
| May 15, 2024 Filed May 17, 2024 13:10 UTC | Accenture plc ACN · Entity 2893 | GrantClass A ordinary shares | 4 | $0.00 | $0.00 |
DisclosureSEC source: 0001467373-24-000171 · wk-form4_1715951432.xml · nonDerivative · entry 1 McKinstry Nancy · CIK 0001294731 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,847 F1 · shares: Grant of Restricted Share Units (RSUs) pursuant to the anti-dilution provisions of previously granted RSU awards, to reflect Accenture plc's payment of a cash dividend. Read SEC document |
| April 26, 2024 Filed Apr 30, 2024 22:05 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 6,850 | $0.00 Strike: $107.14 | $0.00 |
DisclosureSEC source: 0001415889-24-011796 · form4-04302024_100447.xml · derivative · entry 2 McKinstry Nancy · CIK 0001294731 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,850 Underlying: Common Shares · 6,850 shares Expires 2034-04-25 F2 · security: Stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| April 26, 2024 Filed Apr 30, 2024 22:05 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 1,866 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-011796 · form4-04302024_100447.xml · nonDerivative · entry 1 McKinstry Nancy · CIK 0001294731 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,089 F1 · shares: These are restricted stock units awarded under the Abbott Laboratories 2017 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in Abbott common shares on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program). Read SEC document |
| February 15, 2024 Filed Feb 20, 2024 14:23 UTC | Accenture plc ACN · Entity 2893 | Tax withholdingClass A ordinary shares | 2 | $372.35 | $744.70 |
DisclosureSEC source: 0001467373-24-000072 · wk-form4_1708439024.xml · nonDerivative · entry 2 McKinstry Nancy · CIK 0001294731 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,843 Read SEC document |
| February 15, 2024 Filed Feb 20, 2024 14:23 UTC | Accenture plc ACN · Entity 2893 | GrantClass A ordinary shares | 4 | $0.00 | $0.00 |
DisclosureSEC source: 0001467373-24-000072 · wk-form4_1708439024.xml · nonDerivative · entry 1 McKinstry Nancy · CIK 0001294731 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,845 F1 · security: Grant of Restricted Share Units (RSUs) pursuant to the anti-dilution provisions of previously granted RSU awards, to reflect Accenture plc's payment of a cash dividend. Read SEC document |
| February 01, 2024 Filed Feb 5, 2024 14:19 UTC | Accenture plc ACN · Entity 2893 | Tax withholdingClass A ordinary shares | 549 | $367.33 | $201,664.88 |
DisclosureSEC source: 0001467373-24-000055 · wk-form4_1707142759.xml · nonDerivative · entry 1 McKinstry Nancy · CIK 0001294731 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,841 Read SEC document |
| January 31, 2024 Filed Feb 1, 2024 22:02 UTC | Accenture plc ACN · Entity 2893 | GrantClass A ordinary shares | 859 | $0.00 | $0.00 |
DisclosureSEC source: 0001467373-24-000038 · wk-form4_1706824928.xml · nonDerivative · entry 1 McKinstry Nancy · CIK 0001294731 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,390 F1 · kind: Represents a grant of restricted share units awarded under the Accenture plc Amended and Restated 2010 Share Incentive Plan. Read SEC document |
| November 15, 2023 Filed Nov 17, 2023 00:15 UTC | Accenture plc ACN · Entity 2893 | GrantClass A ordinary shares | 5 | $0.00 | $0.00 |
DisclosureSEC source: 0001467373-23-000379 · wk-form4_1700180128.xml · nonDerivative · entry 1 McKinstry Nancy · CIK 0001294731 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,531 F1 · security: Grant of Restricted Share Units (RSUs) pursuant to the anti-dilution provisions of previously granted RSU awards, to reflect Accenture plc's payment of a cash dividend. Read SEC document |
| August 15, 2023 Filed Aug 16, 2023 20:26 UTC | Accenture plc ACN · Entity 2893 | GrantClass A ordinary shares | 5 | $0.00 | $0.00 |
DisclosureSEC source: 0001467373-23-000270 · wf-form4_169221755000104.xml · nonDerivative · entry 1 McKinstry Nancy · CIK 0001294731 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,526 F1 · security: Grant of Restricted Share Units (RSUs) pursuant to the anti-dilution provisions of previously granted RSU awards, to reflect Accenture plc's payment of a cash dividend. Read SEC document |
| May 15, 2023 Filed May 16, 2023 20:17 UTC | Accenture plc ACN · Entity 2893 | GrantClass A ordinary shares | 5 | $0.00 | $0.00 |
DisclosureSEC source: 0001467373-23-000192 · wf-form4_168426822432939.xml · nonDerivative · entry 1 McKinstry Nancy · CIK 0001294731 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,521 F1 · security: Grant of Restricted Share Units (RSUs) pursuant to the anti-dilution provisions of previously granted RSU awards, to reflect Accenture plc's payment of a cash dividend. Read SEC document |
| April 28, 2023 Filed May 2, 2023 23:57 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 9,861 | $0.00 Strike: $110.12 | $0.00 |
DisclosureSEC source: 0001415889-23-007136 · form4-05022023_110549.xml · derivative · entry 2 McKinstry Nancy · CIK 0001294731 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,861 Underlying: Common Shares · 9,861 shares Expires 2033-04-27 F2 · security: Stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| April 28, 2023 Filed May 2, 2023 23:57 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 1,816 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-007136 · form4-05022023_110549.xml · nonDerivative · entry 1 McKinstry Nancy · CIK 0001294731 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,223 F1 · shares: These are restricted stock units awarded under the Abbott Laboratories 2017 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in Abbott common shares on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program). Read SEC document |
| February 15, 2023 Filed Feb 17, 2023 14:18 UTC | Accenture plc ACN · Entity 2893 | Tax withholdingClass A ordinary shares | 2 | $284.90 | $569.80 |
DisclosureSEC source: 0001467373-23-000099 · wf-form4_167664350190169.xml · nonDerivative · entry 2 McKinstry Nancy · CIK 0001294731 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,516 Read SEC document |
| February 15, 2023 Filed Feb 17, 2023 14:18 UTC | Accenture plc ACN · Entity 2893 | GrantClass A ordinary shares | 4 | $0.00 | $0.00 |
DisclosureSEC source: 0001467373-23-000099 · wf-form4_167664350190169.xml · nonDerivative · entry 1 McKinstry Nancy · CIK 0001294731 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,518 F1 · security: Grant of Restricted Share Units (RSUs) pursuant to the anti-dilution provisions of previously granted RSU awards, to reflect Accenture plc's payment of a cash dividend. Read SEC document |
| February 01, 2023 Filed Feb 2, 2023 21:52 UTC | Accenture plc ACN · Entity 2893 | GrantClass A ordinary shares | 1,127 | $0.00 | $0.00 |
DisclosureSEC source: 0001467373-23-000073 · wf-form4_167537470534715.xml · nonDerivative · entry 1 McKinstry Nancy · CIK 0001294731 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,514 F1 · kind: Represents a grant of restricted share units awarded under the Accenture plc Amended and Restated 2010 Share Incentive Plan. Read SEC document |
| January 26, 2023 Filed Jan 30, 2023 21:16 UTC | Accenture plc ACN · Entity 2893 | Tax withholdingClass A ordinary shares | 400 | $274.10 | $109,639.00 |
DisclosureSEC source: 0001467373-23-000061 · wf-form4_167511334631084.xml · nonDerivative · entry 1 McKinstry Nancy · CIK 0001294731 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,387 Read SEC document |
| November 15, 2022 Filed Nov 17, 2022 22:49 UTC | Accenture plc ACN · Entity 2893 | GrantClass A ordinary shares | 4 | $0.00 | $0.00 |
DisclosureSEC source: 0001467373-22-000342 · wf-form4_166872532140304.xml · nonDerivative · entry 1 McKinstry Nancy · CIK 0001294731 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,787 F1 · security: Grant of Restricted Share Units (RSUs) pursuant to the anti-dilution provisions of previously granted RSU awards, to reflect Accenture plc's payment of a cash dividend. Read SEC document |
| August 15, 2022 Filed Aug 17, 2022 20:34 UTC | Accenture plc ACN · Entity 2893 | GrantClass A ordinary shares | 3 | $0.00 | $0.00 |
DisclosureSEC source: 0001467373-22-000254 · wf-form4_166076847251526.xml · nonDerivative · entry 1 McKinstry Nancy · CIK 0001294731 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,783 F1 · security: Grant of Restricted Share Units (RSUs) pursuant to the anti-dilution provisions of previously granted RSU awards, to reflect Accenture plc's payment of a cash dividend. Read SEC document |
| May 13, 2022 Filed May 17, 2022 12:59 UTC | Accenture plc ACN · Entity 2893 | GrantClass A ordinary shares | 4 | $0.00 | $0.00 |
DisclosureSEC source: 0001467373-22-000172 · wf-form4_165279237951517.xml · nonDerivative · entry 1 McKinstry Nancy · CIK 0001294731 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,780 F1 · security: Grant of Restricted Share Units (RSUs) pursuant to the anti-dilution provisions of previously granted RSU awards, to reflect Accenture plc's payment of a cash dividend. Read SEC document |
| April 29, 2022 Filed May 3, 2022 22:09 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 7,846 | $0.00 Strike: $115.46 | $0.00 |
DisclosureSEC source: 0001415889-22-004551 · form4-05032022_030513.xml · derivative · entry 2 McKinstry Nancy · CIK 0001294731 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,846 Underlying: Common Shares · 7,846 shares Expires 2032-04-28 F2 · security: Stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| April 29, 2022 Filed May 3, 2022 22:09 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 1,602 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-22-004551 · form4-05032022_030513.xml · nonDerivative · entry 1 McKinstry Nancy · CIK 0001294731 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,407 F1 · shares: These are restricted stock units awarded under the Abbott Laboratories 2017 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in Abbott common shares on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program). Read SEC document |
| February 24, 2022 Filed Feb 25, 2022 22:23 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 6,280 | $0.00 Strike: $29.84 | $0.00 |
DisclosureSEC source: 0001415889-22-001883 · form4-02252022_020241.xml · derivative · entry 3 McKinstry Nancy · CIK 0001294731 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 6,280 shares Expires 2022-04-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| February 24, 2022 Filed Feb 25, 2022 22:23 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 1,614 | $116.43 | $187,909.95 |
DisclosureSEC source: 0001415889-22-001883 · form4-02252022_020241.xml · nonDerivative · entry 2 McKinstry Nancy · CIK 0001294731 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,805 Read SEC document |
| February 24, 2022 Filed Feb 25, 2022 22:23 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 6,280 | $29.84 | $187,393.94 |
DisclosureSEC source: 0001415889-22-001883 · form4-02252022_020241.xml · nonDerivative · entry 1 McKinstry Nancy · CIK 0001294731 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,419 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 15, 2022 Filed Feb 17, 2022 22:04 UTC | Accenture plc ACN · Entity 2893 | Tax withholdingClass A ordinary shares | 2 | $330.34 | $660.68 |
DisclosureSEC source: 0001467373-22-000120 · wf-form4_164513541708712.xml · nonDerivative · entry 2 McKinstry Nancy · CIK 0001294731 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,776 Read SEC document |
| February 15, 2022 Filed Feb 17, 2022 22:04 UTC | Accenture plc ACN · Entity 2893 | GrantClass A ordinary shares | 4 | $0.00 | $0.00 |
DisclosureSEC source: 0001467373-22-000120 · wf-form4_164513541708712.xml · nonDerivative · entry 1 McKinstry Nancy · CIK 0001294731 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,778 F1 · security: Grant of Restricted Share Units (RSUs) pursuant to the anti-dilution provisions of previously granted RSU awards, to reflect Accenture plc's payment of a cash dividend. Read SEC document |
| February 03, 2022 Filed Feb 4, 2022 22:02 UTC | Accenture plc ACN · Entity 2893 | Tax withholdingClass A ordinary shares | 566 | $347.95 | $196,941.23 |
DisclosureSEC source: 0001467373-22-000073 · wf-form4_164401211995992.xml · nonDerivative · entry 1 McKinstry Nancy · CIK 0001294731 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,774 Read SEC document |
| January 26, 2022 Filed Jan 27, 2022 22:18 UTC | Accenture plc ACN · Entity 2893 | GrantClass A ordinary shares | 911 | $0.00 | $0.00 |
DisclosureSEC source: 0001467373-22-000045 · wf-form4_164332186136981.xml · nonDerivative · entry 1 McKinstry Nancy · CIK 0001294731 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,340 Read SEC document |
| November 15, 2021 Filed Nov 16, 2021 22:09 UTC | Accenture plc ACN · Entity 2893 | GrantClass A ordinary shares | 4 | $0.00 | $0.00 |
DisclosureSEC source: 0001467373-21-000274 · wf-form4_163710056112191.xml · nonDerivative · entry 1 McKinstry Nancy · CIK 0001294731 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,429 F1 · security: Grant of Restricted Share Units (RSUs) pursuant to the anti-dilution provisions of previously granted RSU awards, to reflect Accenture plc's payment of a cash dividend. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.